Clinical Trials

This phase II trial studies how well PI3K/mTOR inhibitor LY3023414 works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body and have come back or do not respond to treatment. PI3K/mTOR inhibitor LY3023414 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well selumetinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway activation mutations that have spread to other places in the body and have come back or do not respond to treatment. Selumetinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back or do not respond to treatment and have spread to other places in the body. Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body and have come back or do not respond to treatment. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body and have come back or do not respond to treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes that have spread to other places in the body and have come back or do not respond to treatment. Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This randomized phase II trial studies how well exercise and low-dose ibuprofen in improving cognitive impairment in patients with colorectal cancer that has not spread to other places in the body who are receiving chemotherapy. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain. Exercise may also help alleviating cognitive difficulties during chemotherapy.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

zzzMarshfield Medical Center

611 Saint Joseph Ave

Marshfield, WI 54449

0401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 3

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449